138 results on '"Chiou, William"'
Search Results
2. Prediction of Clinical Drug–Drug Interactions of Veliparib (ABT-888) with Human Renal Transporters (OAT1, OAT3, OCT2, MATE1, and MATE2K)
3. Quantitative measurements of corticosteroids in ex vivo samples using on-line SPE-LC/MS/MS
4. Quantitation of Plasma Membrane Drug Transporters in Kidney Tissue and Cell Lines Using a Novel Proteomic Approach Enabled a Prospective Prediction of Metformin Disposition
5. Novel insights in drug transporter sciences: the year 2021 in review.
6. Simultaneous quantification of malonyl-CoA and several other short-chain acyl-CoAs in animal tissues by ion-pairing reversed-phase HPLC/MS
7. Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome
8. Endothelin receptors in human smooth muscle cells: antagonist potency differs on agonist-evoked responses
9. Quantitation of plasma membrane drug transporters enables bottom-up PBPK modeling of transporter substrates
10. Direct determination of endothelin receptor antagonist levels in plasma using a scintillation proximity assay
11. Endothelin Stimulates Glucose Uptake and GLUT4 Translocation via Activation of Endothelin ETA Receptor in 3T3-L1 Adipocytes
12. Discovery of a series of pyrrolidine-based endothelin receptor antagonists with enhanced ET A receptor selectivity
13. SV40 virus transformation down-regulates endothelin receptor
14. Pharmacology of A-216546: a highly selective antagonist for endothelin ET A receptor
15. No Inhibition of MATE1/2K-Mediated Renal Creatinine Secretion Predicted with Ritonavir or Cobicistat
16. Validation of a total IC50 method which enables in vitro assessment of transporter inhibition under semi-physiological conditions
17. Increased O-Linked GlcNAc Is Not Sufficient to Induce Insulin-Resistance in 3T3L1 Adipocytes
18. Glucosamine Induced Insulin Resistance in 3T3L1 Adipocytes is Not Prevented by Thiazolidinediones
19. Validation of a total IC 50 method which enables in vitro assessment of transporter inhibition under semi-physiological conditions.
20. In vitroOATP1B1 and OATP1B3 inhibition is associated with observations of benign clinical unconjugated hyperbilirubinemia
21. Discovery and SAR development of thienopyridones: A class of small molecule AMPK activators
22. Discovery of adamantane ethers as inhibitors of 11β-HSD-1: Synthesis and biological evaluation
23. Adamantane sulfone and sulfonamide 11-β-HSD1 Inhibitors
24. Discovery and Metabolic Stabilization of Potent and Selective 2-Amino-N-(adamant-2-yl) Acetamide 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitors
25. Adamantane 11-β-HSD-1 inhibitors: Application of an isocyanide multicomponent reaction
26. Discovery of orally active butyrolactam 11β-HSD1 inhibitors
27. Synthesis and structural activity relationship of 11β-HSD1 inhibitors with novel adamantane replacements
28. Synthesis and biological evaluation of heterocycle containing adamantane 11β-HSD1 inhibitors
29. Microarrayed Compound Screening (μARCS) to Identify Activators and Inhibitors of AMP-Activated Protein Kinase
30. Pharmacology of endothelin receptor antagonists ABT-627, ABT-546, A-182086 and A-192621: in vitro studies
31. New Antimitotic Agents with Activity in Multi-Drug-Resistant Cell Lines and in Vivo Efficacy in Murine Tumor Models
32. Pyrrolidine-3-carboxylic Acids as Endothelin Antagonists. 5. Highly Selective, Potent, and Orally Active ETA Antagonists
33. ‘Irreversible’ Endothelin-1 Binding Does Not Prohibit ABT-627 From Reversing Endothelin-1-Induced Effects
34. Internalization of Type-A Endothelin Receptor
35. In vitro OATP1B1 and OATP1B3 inhibition is associated with observations of benign clinical unconjugated hyperbilirubinemia.
36. Design, Synthesis, and Activity of a Series of Pyrrolidine-3-carboxylic Acid-Based, Highly Specific, Orally Active ETB Antagonists Containing a Diphenylmethylamine Acetamide Side Chain
37. Pyrrolidine-3-carboxylic Acids as Endothelin Antagonists. 4. Side Chain Conformational Restriction Leads to ETB Selectivity
38. Discovery of a series of pyrrolidine-based endothelin receptor antagonists with enhanced ETA receptor selectivity
39. Pharmacology of A-216546: a highly selective antagonist for endothelin ETA receptor
40. The effects of diminishing albumin binding to some Endothelin receptor antagonists
41. Pyrrolidine-3-carboxylic Acids as Endothelin Antagonists. 3. Discovery of a Potent, 2-Nonaryl, Highly Selective ETA Antagonist (A-216546)
42. Potent and Selective Non-Benzodioxole-Containing Endothelin-A Receptor Antagonists
43. Human astrocytoma U138MG cells express predominantly type-A endothelin receptor
44. Endothelins and endothelin receptor antagonists: Binding to plasma proteins
45. Azole Endothelin Antagonists. 3. Using Δ log P as a Tool To Improve Absorption
46. 2,4-Diarylpyrrolidine-3-carboxylic AcidsPotent ETA Selective Endothelin Receptor Antagonists. 1. Discovery of A-127722
47. Azole Endothelin Antagonists. 2. Structure−Activity Studies
48. Azole Endothelin Antagonists. 1. A Receptor Model Explains an Unusual Structure−Activity Profile
49. Dissociation Characteristics of Endothelin ETA Receptor Agonists and Antagonists
50. Oxidant-Induced Activation of Protein Kinase C in Uc11mg Cells
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.